Neuronetics, Inc. announced an expanded commercial partnership with Transformations Care Network. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients. With an extensive network of facilities strategically located across six states and an ambitious roadmap for further expansion, TCN's comprehensive five-year exclusive agreement with Neuronetics stands as a pivotal advancement in broadening patient access to innovative NeuroStar TMS treatments.

This is particularly significant in the context of addressing major depressive disorder (MDD), including treatment-resistant depression (TRD), a condition that presents substantial challenges in mental health care due to the complexity and difficulty in achieving remission with conventional treatments. NeuroStar TMS therapy offers a beacon of hope for individuals grappling with MDD, providing a non-invasive, FDA-cleared treatment that has demonstrated efficacy in cases where traditional pharmacological interventions have failed. By integrating NeuroStar TMS into its array of mental health services, TCN not only elevates the standard of care available to patients but also embodies a forward-thinking approach to mental health treatment.

This initiative underscores a commitment to embracing advanced technologies and treatments that can make a meaningful difference in the lives of those affected by some of the most intractable forms of depression.